+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Artificial Pancreas Device Systems Market Size, Share & Trends Analysis Report by Device Type (Threshold Suspend Device Systems, Control-to-Range Systems), by Region, and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 110 Pages
  • April 2022
  • Region: Global
  • Grand View Research
  • ID: 4538776
The global artificial pancreas device systems market size is anticipated to reach USD 980.95 million by 2030, expanding at a CAGR of 18.94% from 2022 to 2030. Increasing geriatric population, growing incidence of diabetes, and the rising prevalence of obesity are the major factors driving the market growth. In addition, industry players are developing new advanced technologies to provide better compliance and integration with IT devices, which is contributing to the market growth.



The outbreak of COVID-19 in the year 2020 has positively impacted the artificial pancreas device systems market, growth owing to the need for diabetes management in COVID-19 patients. Moreover, COVID-19 recovered diabetes patients have developed resistance to insulin, and the traditional injections fail to provide proper management. Artificial pancreas device systems (APDS) can replace the need for frequent sugar level checks and control blood glucose levels. These factors are anticipated to create huge growth opportunities for market players during the forecast period.

Moreover, regulatory bodies such as FDA are continuously approving new and innovative products, thus increasing the reach of the companies in various markets. For instance, in June 2017, Medtronic launched its latest artificial pancreas system in the U.S. market. This device is capable of automatically delivering insulin to patients when they need it. Similarly, in May 2019, Beta Bionics, Inc. & Zealand Pharma initiated an in-home trial of the iLet Bionic Pancreas system, a dual-hormone pump system intended to automatically deliver dasiglucagon and insulin.

Artificial Pancreas Device Systems Market Highlights
- Based on device type, the threshold suspended device system accounted for the largest market share of 74.72% in 2021; this device is used majorly for hypoglycemic conditions and automatically takes action when the patient is unable to respond.
- On the contrary, the CTT segment is presumed to witness exponential growth throughout the forecast period, as it is a fully automated system that minimizes patient intervention.
- North America artificial pancreas device systems market dominated with around 46.08% market share in 2021, owing to the high patient awareness levels coupled with high prevalence of obesity, as well as presence of major players in the region.
- Asia Pacific is expected to grow at a rapid pace over the forecast owing, to the presence of untapped opportunities, increasing healthcare funding, and government initiatives to spread awareness about diabetes.



This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Artificial Pancreas Device Systems Market

What is the estimated value of the Global Artificial Pancreas Device Systems Market?

The Global Artificial Pancreas Device Systems Market was estimated to be valued at $244.9 Million in 2022.

What is the growth rate of the Global Artificial Pancreas Device Systems Market?

The growth rate of the Global Artificial Pancreas Device Systems Market is 18.9%, with an estimated value of $981.0 Million by 2030.

What is the forecasted size of the Global Artificial Pancreas Device Systems Market?

The Global Artificial Pancreas Device Systems Market is estimated to be worth $981.0 Million by 2030.

Who are the key companies in the Global Artificial Pancreas Device Systems Market?

Key companies in the Global Artificial Pancreas Device Systems Market include Medtronic, Bigfoot Biomedical, Johnson & Johnson Services Inc., Tandem Diabetes Care, Inc., Pancreum, Inc. and Beta Bionics.

Table of Contents

Chapter 1. Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Device Type
1.1.2 Regional Scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased Database:
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.2 Volume Price Analysis (Model 2)
1.6.2.1 Approach 2: Volume Price Analysis
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2. Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3. Artificial Pancreas Device Systems Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 User Perspective Analysis
3.3.1 Consumer Behavior Analysis
3.3.2 Market Influencer Analysis
3.4 List of Key End Users
3.5 Market Dynamics
3.5.1 Market Driver Analysis
3.5.1.1 Increasing Prevalence Of Diabetes
3.5.1.2 Intensive R&D Efforts by Industry Players
3.5.1.3 Rising Demand For Automated Systems For Glycemic Control
3.5.1.4 Increasing Obese Population & Sedentary Lifestyle
3.5.2 Market Restraints Analysis
3.5.2.1 High Cost Of Device Systems and Safety Concern
3.5.2.2 Stringent Regulatory Framework Stalling The Market
3.5.3 Market Opportunities Analysis
3.5.3.1 Increasing Awareness About Diabetes Preventive Care
3.6 Artificial Pancreas Device Systems: Market Analysis Tools
3.6.1 Industry Analysis-Porter’s
3.6.2 Swot Analysis, by Pest
3.7 Impact of COVID-19 on Market & Post Pandemic Insights
Chapter 4. Artificial Pancreas Device Systems Market: Segment Analysis, by Device Type, 2017-2030 (USD Million)
4.1 Definition and Scope
4.2 Device Type Market Share Analysis, 2021 & 2030
4.3 Segment Dashboard
4.4 Global Artificial Pancreas Device Systems Market, by Device Type, 2017 to 2030
4.5 Market Size & Forecasts and Trend Analyses, 2017 to 2030
4.5.1 Threshold Suspend Device Systems
4.5.1.1 Threshold Suspend Device Systems Market, 2017-2030 (USD Million)
4.5.2 Control-To-Range (Ctr) Systems
4.5.2.1 Control-To-Range (Ctr) Systems Market, 2017-2030 (USD Million)
4.5.3 Control-To-Target (Ctt) Systems
4.5.3.1 Control-To-Target (Ctt) Systems Market, 2017-2030 (USD Million)
Chapter 5. Artificial Pancreas Device Systems Market: Regional Market Analysis, by Device Type, and by Product Type, 2017-2030 (USD Million)
5.1 Definition & Scope
5.2 Regional Market Share Analysis, 2021 & 2030
5.3 Regional Market Dashboard
5.4 Regional Market Snapshot
5.5 Market Size, & Forecasts, Volume and Trend Analysis, 2021 to 2030
5.6 North America
5.5.1 North America Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.5.2 U.S.
5.5.2.1 U.S. Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.5.3 Canada
5.5.3.1 Canada Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.7 Europe
5.5.1 Europe Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.5.2 U.K.
5.5.2.1 U.K. Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.5.3 Germany
5.5.3.1 Germany Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.5.4 France
5.5.4.1 France Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.5.5 Italy
5.5.5.1 Italy Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.5.6 Spain
5.5.5.1 Spain Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.8 Asia Pacific
5.8.1 Asia Pacific Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.8.2 Japan
5.8.2.1 Japan Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.8.3 China
5.8.3.1 China Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.8.4 India
5.8.4.1 India Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.8.5 Australia
5.8.5.1 Australia Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.8.6 South Korea
5.8.5.1 South Korea artificial pancreas device systems market, 2017-2030 (USD Million)
5.9 Latin America
5.9.1 Latin America Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.9.2 Brazil
5.9.2.1 Brazil artificial pancreas device systems market, 2017-2030 (USD Million)
5.9.3 Mexico
5.9.3.1 Mexico Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.9.4 Argentina
5.9.4.1 Argentina Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.9.5 Colombia
5.9.5.1 Colombia artificial pancreas device systems market, 2017-2030 (USD Million)
5.10 MEA
5.10.1 MEA Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.10.2 South Africa
5.10.2.1 South Africa Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.10.3 Saudi Arabia
5.10.3.1 Saudi Arabia Artificial Pancreas Device Systems Market, 2017-2030 (USD Million)
5.10.4 UAE
5.10.4.1 UAE artificial pancreas device systems market, 2017-2030 (USD Million)
Chapter 6. Artificial Pancreas Device Systems Market-Competitive Analysis
6.1 Recent Developments & Impact Analysis, by Key Market Participants
6.2 Company Categorization
6.2.1 Innovators
6.2.2 Market Leaders
6.3 Vendor Landscape
6.3.1 Key Company Market Share Analysis, 2021
6.3.2 Major Deals and Strategic AllianceS
6.3.2.1 New Product Launch
6.3.2.2 Expansion
6.3.2.3 Acquistion
6.3.3 Market Entry Strategies
6.4 Company Profiles
6.4.1 Medtronic
6.4.1.1 Company overview
6.4.1.2 Financial performance
6.4.1.3 Product benchmarking
6.4.1.4 Strategic initiatives
6.4.2 Bigfoot Biomedical
6.4.2.1 Company overview
6.4.2.2 Financial performance
6.4.2.3 Product benchmarking
6.4.2.4 Strategic initiatives
6.4.3 Johnson & Johnson Services Inc.
6.4.3.1 Company overview
6.4.3.2 Financial performance
6.4.3.3 Product benchmarking
6.4.3.4 Strategic initiatives
6.4.4 Tandem Diabetes Care, Inc.
6.4.4.1 Company overview
6.4.4.2 Financial performance
6.4.4.3 Product benchmarking
6.4.4.4 Strategic initiatives
6.4.5 Pancreum, Inc.
6.4.5.1 Company overview
6.4.5.2 Financial performance
6.4.5.3 Product benchmarking
6.4.5.4 Strategic initiatives
6.4.6 TypeZero Technologies, LLC
6.4.6.1 Company overview
6.4.6.2 Financial performance
6.4.6.3 Product benchmarking
6.4.6.4 Strategic initiatives
6.4.7 Beta Bionics
6.4.6.1 Company overview
6.4.6.2 Financial performance
6.4.6.3 Product benchmarking
6.4.6.4 Strategic initiatives

Companies Mentioned

  • Medtronic
  • Bigfoot Biomedical
  • Johnson & Johnson Services Inc.
  • Tandem Diabetes Care, Inc.
  • Pancreum, Inc.
  • Typezero Technologies, LLC
  • Beta Bionics

Methodology

Loading
LOADING...